Intelligence · Patents
Patents expiring in 2035
Annual patent cliff calendar for 2035 — US pharmaceutical patents by expiration date.
- Patents
- 1,447
Quick answer
1,447 indexed pharmaceutical patents have expiration dates in 2035. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 9169297
Subgenomic replicons of the flavivirus dengue
granted -
US 9175280
Methods and compositions for treating hemophilia B
granted -
US 9176122
Biomarkers for predicting response to immunosuppressive therapy
granted -
US 9173943
Imprinted polymer nanoparticles
granted -
US 9173839
Anionic lipids and lipid nano-structures and methods of producing and using same
granted -
US 9173896
RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions
granted -
US 9173840
Multifunctional self-assembling polymeric nanosystems
granted -
US 9173862
Methods and compositions for treating and identifying compounds to treat age-related macular degeneration
granted -
US 9175065
FGFR extracellular domain acidic region muteins
granted -
US 9173849
Solid pharmaceutical composition
granted -
US 9173882
Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors
granted -
US 9173886
Antiviral compounds and methods of use thereof
granted -
US 9173897
Molecular targets for ALS and related disorders
granted -
US 9173898
Methods of treating giardiasis
granted -
US 9173917
Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug
granted -
US 9173932
Vibrio cholerae O139 conjugate vaccines
granted -
US 9173951
Carbohydrate-based drug delivery polymers and conjugates thereof
granted -
US 9173957
FGFR2 fusion proteins comprising C-terminal deletion mutants of FGFR2-IIIC
granted -
US 9173947
Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom
granted -
US 9173975
Reparative cell delivery via hyaluronic acid vehicles
granted -
US 9175037
Neuromedin U derivative
granted -
US 9174411
Laminated sheet and process for producing the same
granted -
US 9175058
Soluble immune response suppressor polypeptides and treatment of multiple sclerosis and other autoimmune diseases
granted -
US 9174917
Bexarotene analogs
granted -
US 9174973
Crystalline forms of azilsartan and preparation and uses thereof
granted -
US 9174964
AMPK-activating piperidinyloxy-substituted 2,3-dihydro-1H-indene-1-amine compounds and pharmaceutical compositions including the same
granted -
US 9175033
Methods for preparing complex multivalent immunogenic conjugates
granted -
US 9175003
Substituted azoanthracene derivatives and intermediates for preparation thereof
granted -
US 9175041
Crystal structures of dolastatin 16, dolamethylleuine and dolaphenvaline, and methods for preparing dolamethylleuine and dolaphenvaline
granted -
US 9175038
Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use
granted -
US 9175057
Immunogenic peptides and methods of use
granted -
US 9174990
2-amino-9-[(2-hydroxymethyl) cyclopropylidenemethyl] purines as antiviral agents
granted -
US 9173966
Luciferin derivatives from bicyclic reactants and aminothiol derivatives and methods of use thereof
granted -
US 9173931
Process for preparing polysaccharide-protein conjugate vaccines
granted -
US 9173880
Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
granted -
US 9175906
Drug particles from freezing onto a surface
granted -
US 9175049
Recombinant mycobacterium avium subsp. paratuberculosis proteins induce immunity and protect against infection
granted -
US 9175062
Human soluble receptor for advanced glycation end products (sRAGE), methods of preparing human sRAGE, and treatment methods using sRAGE
granted -
US 9175290
Compositions and methods for inhibiting expression of TMPRSS6 gene
granted -
US 9175070
Neutralizing antibodies to HIV-1 and their use
granted -
US 9175349
Methods of diagnosing endometriosis
granted -
US 9175264
Postnatal stem cells and uses thereof
granted -
WO 2015165821
VERFAHREN UND VORRICHTUNG ZUR HERSTELLUNG EINER PHARMAZEUTISCHEN ZUSAMMENSETZUNG
granted -
US 9181253
Adenosine receptor agonists, partial agonists, and antagonists
granted -
US 9180122
5- or 6-substituted 3-hydroxy-2 (1 H)-pyridinones as D-amino acid oxidase (DAAO) inhibitors in therapy of diseases such as schizophrenia, cognitive disorder and pain
granted -
US 9180161
CAR peptide for homing, diagnosis and targeted therapy for pulmonary and fibrotic disorders
granted -
US 9181206
Dual-acting oxazole antihypertensive agents
granted -
US 9181222
Protein kinase C inhibitors and uses thereof
granted
Frequently asked questions
How many pharma patents expire in 2035?
1,447 published patents in our USPTO index have expiration dates falling in calendar year 2035.